Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Current factor IX (FIX) products display a half-life (t(1/2)) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients with hemophilia B. This open-label, dose-escalation trial in previously treated adult subjects with hemophilia B examined the safety and pha...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Shapiro, Amy D., Ragni, Margaret V., Valentino, Leonard A., Key, Nigel S., Josephson, Neil C., Powell, Jerry S., Cheng, Gregory, Thompson, Arthur R., Goyal, Jaya, Tubridy, Karen L., Peters, Robert T., Dumont, Jennifer A., Euwart, Donald, Li, Lian, Hallén, Bengt, Gozzi, Peter, Bitonti, Alan J., Jiang, Haiyan, Luk, Alvin, Pierce, Glenn F.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2012
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3265197/
https://ncbi.nlm.nih.gov/pubmed/22110246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-367003
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker